ArticleClinical and translational allergy2026
Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTralokinumab, an interleukin-13 (IL-13) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate-to-severe atopic dermatitis (AD). This study aims to evaluate clinical and immunological outcome upon tralokinumab treatment in a real-world cohort of patients with moderate-to-severe AD.
methodsWe recruited 81 AD patients receiving tralokinumab, performing clinical assessments (oScorad, IGA, BSA, DLQI, pruritus-VAS) at baseline and months 3, 6, 9, and 12. For immunophenotyping (n = 25), PBMCs were collected at baseline and months 6/12. Peripheral T-cell subsets, CLA, OX40, TFH, and cytokines (IL-4, IL-13, IL-17A, IL-10, IFNγ) were analyzed via multiparametric flow cytometry. Serum total/specific IgEs were measured by ImmunoCap and eosinophils by differential blood counts.
resultsTralokinumab treatment induced a continued clinical response: at 12 months, oScorad and BSA decreased by 60.8% and 78.8%. CLA
conclusionsIn real-world practice, tralokinumab achieves robust clinical benefit and a rebalanced systemic immune pattern. Selective IL-13 blockade reshapes T-cell function, shifting the immune balance from Th2/Th17 dominance toward Th1/regulatory profiles, suggesting immunomodulatory effects consistent with disease modification. Future studies are needed to determine the long-term stability of these immunological changes following treatment prolongation or interruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.